Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health (NASDAQ: SNWV) reported preliminary Q4 2025 revenue of $13.3–$13.4 million, a 29–30% increase versus Q4 2024 and the company’s highest quarterly revenue ever.
Rhea-AI Summary
Sanuwave Health (NASDAQ: SNWV) reported preliminary Q4 2025 revenue of $13.3–$13.4 million, a 29–30% increase versus Q4 2024 and the company’s highest quarterly revenue ever. Full-year 2025 revenue rose to $44.3–$44.4 million, up 36% year-over-year and a record for the company. Management said Q4 results are within prior guidance and are based on preliminary quarter-end analysis that may be adjusted during financial close. The company noted market disruption from reduced reimbursement for skin-substitutes and allografts, and said it is adding partners and sales channels while adapting its business model. Final audited results and further detail will be released with the March earnings report.
Positive
- Q4 revenue of $13.3–$13.4M, a 29–30% YoY increase
- Full-year 2025 revenue of $44.3–$44.4M, +36% YoY (record)
- Q4 results within prior guidance, indicating execution vs plan
Negative
- Preliminary results may be adjusted during quarter-end close
- Market disruption from reduced reimbursement for skin-substitutes and allografts could pressure near-term demand
- Company undergoing business model transition, which could create execution risk
Details
News Market Reaction – SNWV
On Jan 9, the day this news came out, SNWV closed 1.24% above the previous close.
Data tracked by StockTitan Argus for the Jan 9 session.
Key Figures
- Q4 2025 revenue (prelim.)
- $13.3–$13.4M
- Fourth quarter 2025, record quarterly revenue
- Q4 2025 YoY growth
- 29–30%
- Increase vs. Q4 2024 revenue
- Full-year 2025 revenue (prelim.)
- $44.3–$44.4M
- All-time record annual revenue
- Full-year 2025 YoY growth
- 36%
- Increase vs. full-year 2024 revenue
Historical Context
-
Announcement of participation in the J.P. Morgan Healthcare Conference.
-
UltraMIST added to Healogics iSupply GPO for broader wound-care access.
-
Record Q3 2025 revenue with strong profitability and raised visibility on outlook.
-
Scheduling of Q3 2025 financial results conference call and webcast.
-
CMS final 2026 fee schedule keeping UltraMIST reimbursement largely unchanged.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fda-approved regulatory
allografts medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Sanuwave is pleased to announce preliminary revenues of
Q4 2025 revenue increased between
Full Year 2025 revenue increased to
EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of
“We’re pleased to once more be on guidance and on track for Q4 and for full year 2025,” said CEO Morgan Frank. “As we discussed when releasing Q3, the second half of 2025 was a time of intense transition in the wound care space as reductions to reimbursement rates for skin-substitutes and allografts profoundly reshaped our market. Periods of such rearrangement are always times of opportunity and Sanuwave has been busy acquiring new partners, new sales channels, and adapting its business model for, while times may change, the fact of patients in need of advanced wound care does not. This space has been a bit of a loose ball drill, and loose balls go to the one who sees them first, moves fastest, and wants them most. I am proud to say that our team excelled in all these things this quarter and it feels good to end the year with another record quarter. We look forward to sharing more about how we are positioning ourselves for the year and opportunities to come when we report earnings in March.”
The preliminary revenue results described herein are based on management’s initial analysis of the fourth quarter ended December 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.